SAN CARLOS, CA, March 4, 2024 -- Glycomine, Inc., a biotechnology company focused on developing new therapies for orphan diseases, announced the presentation of summary findings from its ongoing Phase...
Athersys is a clinical-stage biotechnology company that has established a pipeline of therapeutic product development programs in multiple disease indications. The company’s product portfolio consists of MultiStem, a non-embryonic stem cell-based approach for treating disease indications in the areas of inflammatory and immune, neurological and cardiovascular disease.
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.